Open
Do sulfonylureas & glinides cause more adverse events & safety versus placebo?
Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Doubtful. So far, no trial evidence yet.
NoUnsureYes
- Belief
- 0.25 (range 0.10–0.70)
- Trials for
- 0
- Trials against
- 0
- Inconclusive
- 1
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 117
- With posted results
- 45
- Published papers
- 7
Of 23 decided analyses: 3 favor sulfonylureas & glinides, 18 find no difference, 2 favor the comparator.
Papers
- Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis.Meta-analysis / systematic review · 2014
- Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.Meta-analysis / systematic review · 2013
- Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies.Meta-analysis / systematic review · 2015
- Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies.Meta-analysis / systematic review · 2008
- Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis.Meta-analysis / systematic review · 2019
- Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis.Trial report · 2025
Trials
- A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on MetforminNCT01682759 · 3 posted results
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy.NCT02033889 · 4 posted results
- A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes MellitusNCT00838903 · 8 posted results
- Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic DyslipidemiaNCT00770653 · 10 posted results
- A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Type 2 Diabetes MellitusNCT01709305 · 12 posted results
- The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride ArmNCT00620282 · 5 posted results
- Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)NCT02973477 · 3 posted results
- Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?NCT02879409